R&D
Phase I Clinical Trial of GXV-001 Initiated in Australia
2022/7/21
GEXVal Inc. is pleased to announce that we have officially initiated phase I clinical trial of its drug candid […]
HREC Approval of the Initiation of Phase 1 Study of GXV-001 in Australia
2022/6/10
GEXVal Inc.June 10, 2022 GEXVal Inc. has invited experienced doctors and specialists from Japan, Australia, Sw […]